Health ❯ Healthcare ❯ Oncology

Melanoma

Immunotherapy Adjuvant Therapy Immune Checkpoint Inhibitors Advanced Melanoma Tumor-Infiltrating Lymphocytes Treatment Options Oncolytic Therapies T-Cell Receptor T-Cells BRAF V600 Mutation Chimeric Antigen Receptor T-Cells Diagnosis Neoadjuvant Therapy Treatment Protocols Targeted Therapy Lung Cancer Immunotherapy Resistance Advanced Melanoma Treatments BRAF-targeted Therapy Vaccines

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

The decision underscores the FDA’s insistence on well‑controlled efficacy data over single‑arm results.

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

TIM‑3 Triplet Therapy Shows Promise in Immunotherapy‑Resistant Melanoma Models

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy